FindMyRecallSubscribe
Class III: unlikely to cause harmOngoing

Teva Pharmaceuticals Nortrel 7/7/7 Recall

Nortrel 7/7/7 (norethindrone and ethinyl estradiol tablets USP- triphasic regimen), pac…

Teva Pharmaceuticals USA, Inc · Parsippany, NJ

Risk level
Class III
Reported by FDA
Feb 21, 2024
Recall ID
D-0322-2024
Check your lot numberHow we source this data

Summary

Teva Pharmaceuticals recalled Nortrel 7/7/7 starting Jan 25, 2024. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-0322-2024 on Feb 21, 2024. Reason: Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets. Status: Ongoing.

Why it was recalled

Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.

Product description

Nortrel 7/7/7 (norethindrone and ethinyl estradiol tablets USP- triphasic regimen), packaged in cartons, each carton contains 6 blister cards, each card contains 28 tablets, Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0555-9012-58

Lot numbers, UPCs & expiration codes

Lot #: 100040731, Exp 7/31/2024

Where it was sold

nationwide

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0322-2024
Classification
Class III
Status
Ongoing
Recall initiated
Jan 25, 2024
FDA report date
Feb 21, 2024
Quantity
19,824 cartons
Recall type
Voluntary: Firm initiated
Recalling firm
Teva Pharmaceuticals USA, Inc

Original FDA data

Every field from FDA enforcement report D-0322-2024, exactly as published.

Show all FDA fields
City
Parsippany
State
NJ
Status
Ongoing
Country
United States
Event ID
93867
Address
400 Interpace Pkwy Bldg A
Code information
Lot #: 100040731, Exp 7/31/2024
Postal code
07054-1120
Report date
Feb 21, 2024
Product type
Drugs
Recall number
D-0322-2024
Classification
Class III
Recalling firm
Teva Pharmaceuticals USA, Inc
Product quantity
19,824 cartons
Reason for recall
Discoloration: discolored tablets (shades of blue) mixed in with the white inert remainder tablets.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Nortrel 7/7/7 (norethindrone and ethinyl estradiol tablets USP- triphasic regimen), packaged in cartons, each carton contains 6 blister cards, each card contains 28 tablets, Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0555-9012-58
Distribution pattern
nationwide
Recall initiation date
Jan 25, 2024
Initial firm notification
Letter
Center classification date
Feb 12, 2024

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0322-2024, published Feb 21, 2024. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls